-
甲状腺癌是最常见的内分泌系统恶性肿瘤, 其病死率在内分泌系统肿瘤中居第一位。甲状腺癌分为分化型和未分化型两种, 其中以分化型甲状腺癌(differentiated thyroid carcinoma, DTC)居多, 其发病率呈逐年上升趋势。DTC分化程度高、恶性程度低、患者生存率高(10年和15年生存率分别可达94.7%和87.4%), 是预后最好的甲状腺癌[1-2]。但是DTC术前和术后分别有21.2%和7.02%的患者会发生肿瘤复发或转移[3], 且一旦发生远处脏器的转移, 患者10年生存率会降低至25%~40%[4]; 若发生骨转移, 10年生存率则会降至20%以下[5]。然而也有文献报道, 如果对转移性DTC患者采取适当的治疗, 其生存期会延长[6]。因此, 甲状腺癌骨转移的研究越来越受到人们的重视。而甲状腺癌骨转移动物模型的建立是研究甲状腺癌骨转移机制和治疗的基础, 故本文将对近年来有关甲状腺癌骨转移动物模型的新进展作一综述。
甲状腺癌骨转移模型的研究
Research progress of animal model of bone metastases of thyroid carcinoma
-
摘要: 甲状腺癌是内分泌系统最常见的恶性肿瘤,其发病率逐年上升,虽然该病预后较好,但若发生骨转移,患者10年生存率将明显降低。目前,甲状腺癌发生骨转移的机制尚不明确,对甲状腺癌骨转移的研究不仅具有重要的临床价值,也有很重要的科研价值。甲状腺癌骨转移动物模型的建立是研究甲状腺癌骨转移机制和治疗的基础,根据其建立方法可分为自发性、化学诱导性、转基因诱导性和移植性4种。Abstract: Thyroid carcinoma is the most common endocrine malignancy, its incidence rate increases year by year.Although the disease has good prognosis, if bone metastases happen, 10-year survival rate of patients will obviously reduce.At present, the mechanism of the occurrence of bone metastases is not clear. The research of bone metastases of thyroid carcinoma not onlyhasimportantclinicalvalue, butalsoscientific value.Animal model of bone metastasis of thyroid carcinoma is the basis to study themechanismand therapy of thyroid carcinoma.According to its establishment methods, it can be divided into four types, including spontaneous type, chemical induced type, transgenic induced type and transplanted type.
-
Key words:
- Thyroid neoplasms /
- Neoplasm metastasis /
- Models, animal
-
[1] Sciuto R, Romano L, Rea S, et al. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol, 2009, 20(10): 1728-1735. doi: 10.1093/annonc/mdp050 [2] Muresan MM, Olivier P, Leclère J, et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer, 2008, 15(1): 37-49. doi: 10.1677/ERC-07-0229 [3] Mihailovic JM, Stefanovic LJ, Malesevic MD, et al. Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nucl Med Commun, 2009, 30(7): 558-564. doi: 10.1097/MNM.0b013e32832cc2ab [4] Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab, 2006, 91(8): 2892-2899. doi: 10.1210/jc.2005-2838 [5] Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung ang bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab, 1986, 63(4): 960-967. doi: 10.1210/jcem-63-4-960 [6] Sugitani I, Fujimoto Y, Yamamoto N, et al. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery, 2008, 143(1): 35-42. doi: 10.1016/j.surg.2007.06.011 [7] Baitei EY, Zou M, Al-Mohanna F, et al. Aberrant BRAF splicingas an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol, 2009, 217(5): 707-715. doi: 10.1002/path.2496 [8] Kogai T, Sajid-Crockett S, Newmarch LS, et al. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J Endocrinol, 2008, 199(2): 243-252. doi: 10.1677/JOE-08-0333 [9] Ahn SH, Henderson Y, Kang Y, et al. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg, 2008, 134(2): 190-197. doi: 10.1001/archoto.2007.36 [10] Younes MN, Kim S, Yigitbasi OG, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther, 2005, 4(8): 1146-1156. doi: 10.1158/1535-7163.MCT-05-0078 [11] Schweppe RE, Kerege AA, Sharma V, et al. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells tomitogen-activatedproteinkinase kinase 1/2 inhibition. Thyroid, 2009, 19(8): 825-835. doi: 10.1089/thy.2008.0362 [12] Cheng SP, Yin PH, Chang YC, et al. Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep, 2010, 23(6): 1721-1727. [13] Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contaminationresultingincelllineredundancyand misidentification. J Clin Endocrinol Metab, 2008, 93(11): 4331-4341. doi: 10.1210/jc.2008-1102 [14] Klopper JP, Berenz A, Hays WR, et al. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res, 2008, 14(2): 589-596. doi: 10.1158/1078-0432.CCR-07-0269 [15] Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther, 2007, 6(6): 1785-1792. doi: 10.1158/1535-7163.MCT-06-0595 [16] Nahari D, Satchi-Fainaro RS, Chen M, et al. Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol Cancer Ther, 2007, 6(4): 1329-1337. doi: 10.1158/1535-7163.MCT-06-0554 [17] Lin X, Zhu B, Liu Y, et al. Follicular thyroid carcinoma invades venous rather than lymphatic vessels. Diagn Pathol, 2010, 5: 8. doi: 10.1186/1746-1596-5-8 [18] Hombach-KlonischS, BialekJ, RadestockY, etal. INSL3hastumorpromoting activity in thyroid cancer. Int J Cancer, 2010, 127(3): 521-531. doi: 10.1002/ijc.25068 [19] Ercolino T, Lombardi A, Becherini L, et al. The Y606C RET mutation causes a receptor gain of function. Clin Endocrinol(Oxf), 2008, 69(2): 253-258. doi: 10.1111/j.1365-2265.2008.03197.x [20] Quidville V, Segond N, Tebbi A, et al. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice. Thyroid, 2009, 19(6): 613-621. doi: 10.1089/thy.2008.0194 [21] Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer, 2010, 18(1): 1-11. doi: 10.1677/ERC-09-0292 [22] Chen MC, Yu CH, Wang SW, et al. Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J Cell Biochem, 2010, 110(6): 1495-1503. doi: 10.1002/jcb.22716 [23] Arcinas A, Yen TY, Kebebew E, et al. Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res, 2009, 8(8): 3958-3968. doi: 10.1021/pr900278c [24] Hoffmann S, Rockenstein A, Ramaswamy A, et al. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol, 2007, 264(1-2): 74-81. doi: 10.1016/j.mce.2006.10.009 [25] Fortin MA, Salnikov AV, Nestor M, et al. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging, 2007, 34(9): 1376-1387. doi: 10.1007/s00259-006-0346-5 [26] Leux C, Guénel P. Risk factors of thyroid tumors: role of environmental and occupational exposures to chemical pollutants. Rev Epidemiol Sante Publique, 2010, 58(5): 359-367. doi: 10.1016/j.respe.2010.05.005 [27] Alfano RW, Leppla SH, Liu S, et al. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther, 2010, 9(1): 190-201. doi: 10.1158/1535-7163.MCT-09-0694 [28] Hombach-KlonischS, BialekJ, RadestockY, etal. INSL3hastumorpromoting activity in thyroid cancer. Int J Cancer, 2010, 127(3): 521-531. doi: 10.1002/ijc.25068 [29] Zatelli MC, Tagliati F, Amodio V, et al. Role of pituitary tumour transforming gene 1 in medullary thyroid carcinoma. Anal Cell Pathol(Amst), 2010, 33(5): 207-216. [30] Henderson YC, Ahn SH, Kang Y, et al. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res, 2008, 14(15): 4908-4914. [31] Nucera C, Nehs MA, Mekel M, et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid, 2009, 19(10): 1077-1084. doi: 10.1089/thy.2009.0055 [32] Kim S, Park YW, Schiff BA, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res, 2005, 11(5): 1713-1721. doi: 10.1158/1078-0432.CCR-04-1908 [33] Sehiff BA, MeMurphy AB, Jasser SA, et al. Epidermal growth factor receptor(EGFR)is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res, 2004, 10(24): 8594-8602. doi: 10.1158/1078-0432.CCR-04-0690 [34] Zou M, Famulski KS, Parhar RS, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100 A4(Mts1)gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab, 2004, 89(12): 6146-6154. doi: 10.1210/jc.2004-0418
计量
- 文章访问数: 944
- HTML全文浏览量: 508
- PDF下载量: 1